Actinium Announces Collaboration With IsoTherapeutics
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it started a collaboration with IsoTherapeutics Group of Houston, TX to complete studies required for introduction of a new manufacturing process for Actimab-A. The new manufacturing process that results in a tenfold improvement of manufacturing yield has been developed by the company internally in collaboration with IsoTherapeutics. IsoTherapeutics will perform additional experiments to generate documentation necessary for regulatory submissions.
Actimab-A is in a multicenter clinical trial for older patients diagnosed with acute myeloid leukemia (AML). Further improvements in manufacturing efficacy are integral components of the drug development process.
“Alpha particle immunotherapy is a new approach in oncology and for such novel technologies manufacturing development is inextricably linked with clinical development,” said Dr. Kaushik J. Dave, the President and CEO of Actinium Pharmaceuticals. “We are encouraged by the big advancements we are making in both areas and confirmation of our methods from our partners and collaborators. These advances have application beyond any individual drug.”